Sight Sciences stock
SGHTNASDAQSight Sciences, Inc., HealthcareISIN US82657M1053
48Score 48 out of 100, Weak
Price and trend
82 / 100
Price history
+42% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 78% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 80).
The price is at its 52-week high. Largest decline in 5 years: 97% (August 2021 to October 2023).
Chart figures for advanced users
- SMA 50$8.92
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.16
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)80
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.45
- The lowest closing price of the last twelve months.
- Resistance$11.01
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Sight Sciences, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $610.81M, is number 75 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $77.36M (down 3.1% year on year) and a loss of $38.43M.
- For fiscal 2026, analysts expect on average revenue of $91.49M (up 18.3%) and adjusted earnings per share of −$0.52.
Show more
- MEQIRI Score 48 out of 100 (Weak): rank 410 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 22.9% a year since 2020, Medical (Devices) median 13.8%.Growth 70
- More cash than debtCash $77.4M, financial debt $42.11M.
Weaknesses
- Loss-makingLoss of $28.4M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$16.91M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 73% a year over the last 12 months.Stability 44
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 16.2% on the twelve months before. Revenue has grown strongly since 2018, at around 39% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 86%, operating −48%, net −50%. Last 12 months: net −32%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Mar 2027in 111 days
- Last reported
- 4 Nov 2026EPS reported −$0.12 (expected −$0.12)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 27.0% since 15 Oct 2026.
- Earnings per share
- −$0.52+19.1%
- Revenue
- $91.49M+1.3%
- Earnings per share
- −$0.44+27.0%
- Revenue
- $102.22M+1.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +25.7%2026 revenue guidance raised to $88 to $92 million (before: $83 to $89 million), and adjusted operating expense guidance lowered.
“Moving to our revenue outlook for full year 2026, we are raising revenue guidance to $88 million to $92 million, which reflects growth of 14% to 19% compared to 2025, versus the prior guidance range of $83 million to $89 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $68,794 in total. 6 insiders sold, $1.17M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Taylor BrentonSale
2 Oct 2026, EVP, Operations & R&D
- Shares
- 2,988
- Price
- $8.85
- Value
- $26,453
- Bauerlein AlisonSale
2 Oct 2026, Chief Operating Officer
- Shares
- 25,260
- Price
- $8.85
- Value
- $223,627
- Rodberg JamesSale
2 Oct 2026, Chief Financial Officer
- Shares
- 7,208
- Price
- $8.85
- Value
- $63,812
Show 10 more
- Badawi DavidSale
1 Oct 2026, Chief Technology Officer
- Shares
- 7,797
- Price
- $9.05
- Value
- $70,555
- Badawi PaulSale
1 Oct 2026, 10 percent owner, officer: President and CEO
- Shares
- 29,653
- Price
- $9.05
- Value
- $268,330
- Hayden Jeremy B.Sale
6 Jul 2026, Chief Legal Officer
- Shares
- 12,733
- Price
- $5.51
- Value
- $70,133
- Badawi DavidSale
6 Jul 2026, Chief Technology Officer
- Shares
- 7,418
- Price
- $5.51
- Value
- $40,858
- Rodberg JamesSale
2 Jul 2026, Chief Financial Officer
- Shares
- 6,902
- Price
- $5.36
- Value
- $36,995
- Bauerlein AlisonSale
2 Jul 2026, Chief Operating Officer
- Shares
- 24,184
- Price
- $5.36
- Value
- $129,626
- Taylor BrentonSale
1 Jul 2026, EVP, Operations & R&D
- Shares
- 2,829
- Price
- $5.42
- Value
- $15,333
- Badawi PaulSale
1 Jul 2026, 10 percent owner, officer: President and CEO
- Shares
- 28,684
- Price
- $5.42
- Value
- $155,467
- Encrantz StaffanPurchase
10 Jun 2026, Board
- Shares
- 14,100
- Price
- $4.88
- Value
- $68,794
- Bauerlein AlisonSale
18 May 2026, Chief Operating Officer
- Shares
- 12,728
- Price
- $5.12
- Value
- $65,167
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Sight Sciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 48
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Senseonics HoldingsSENS $684.97M44
- Xvivo PerfusionXVIVO.ST $653.35M50
- Pacific Biosciences of CaliforniaPACB $649.64M38
- Tactile Systems TechnologyTCMD $607.75M68
- Anteris Technologies GlobalAVR $604.24M35
- MedistimMEDI.OL $599.88M80
- Ion Beam ApplicationsIBAB.BR $547.66M58
- Avita MedicalRCEL $533.99M44
ETFs that hold Sight Sciences
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.